1.13 - 33
Join Discuss about BYSI with like-minded investors
Upside: -CYCN +16% (announces Global Licensing agreement with Akebia Therapeutics for Praliciguat; eligible to receive up to $585M in milestone payments) -SFIX +12% (earnings, guidance) -REVG +10% (earnings, guidance) -CHS +9.9% (earnings, guidance) -EVOK +8.4% (announces FDA Orange Book Listing of U.S. Patent for Gimoti) -ASO +7.2% (earnings, guidance) -MCF +6.6% (to be acquired by Independence Energy in all stock transaction valued at ~$5.7B) -JILL +6.3% (earnings, guidance) -MRVL +5.6% (earnings, guidance) -BYSI +4.8% (announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data) -THO +4.1% (earnings) -STX +3.7% (raises guidance) -TSLA +2.9% (strong China May passenger vehicle sales) -INO +2.6% (expands partnership with Advaccine to conduct global Phase III efficacy trial of COVID-19 DNA vaccine candidate, INO-4800) -OTLK +2.3% (reports completion of patient dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial) -FTCI +1.4% (earnings, guidance; raising prices) -LUV +1.2% (guidance) Downside: -PLBY -10% (files to offer 4.0M shares) -COUP -8.9% (earnings, guidance; Tony Tiscornia promoted to CFO) -TIGR -7.6% (files to sell 6.5M ADS) -HSTO -7.5% (announces 6.0M share direct offering priced at $1.10/shr) -LESL -5.7% (to sell 24.5M shares for holders) -HQY -5.5% (earnings, guidance) -KDP -4.9% (files to sell 28M common share secondary offering on behalf of Mondelez International) -FTCI -4.7% (earnings, guidance; raising prices) -FSLY -1.7% (hearing Fastly edge CDN platform is having issues causing internet outages) -ETSY -1.3% (files proposed private offering of $1.0B of convertible senior notes) -WBA -1.3% (AMZN reportedly to offer discounted pharmacy services targeting uninsured and those paying cash)
121 Replies 10 👍 14 🔥
Next Dividend Date
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.